Clinical Trials in Nashville

Showing 9881-9900 of 17,403 trials

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale

NCT02502149

The primary objective of the study is to compare the pharmacokinetic (PK) of recombinant coagulation factor VIII Fc fusion protein (rFVIIIFc) manufactured at the current scale of 2000 L (2K) to the PK of rFVIIIFc manufactured at the 15,000 L (15K) scale in previously treated participants with severe hemophilia A. The secondary objectives are: to characterize the PK of rFVIIIFc manufactured at the 15K scale at the 15K baseline and after 13 weeks of treatment; to characterize the PK of rFVIIIFc manufactured at the 15K scale at 1000 IU/vial and 6000 IU/vial strengths; and to evaluate the safety of rFVIIIFc manufactured at the 15K scale.

Severe Hemophilia A

Bioverativ Therapeutics Inc.24 participantsStarted Aug 2015

Los Angeles, California, United States • Chicago, Illinois, United States • Indianapolis, Indiana, United States +12 more locations

COMPLETEDPhase 3156 miles

Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia

NCT00084071

The purpose of this study is to determine whether tifacogin is effective and safe in the treatment of patients with severe community-acquired pneumonia.

Pneumonia

Novartis Pharmaceuticals2,136 participantsStarted May 2004

Mobile, Alabama, United States • Loma Linda, California, United States • Los Angeles, California, United States +147 more locations

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale

Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia

Find Trials by Condition in Nashville

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder

Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections

Efficacy, Safety, and Pharmacokinetics of QAW039

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

Dose Finding Study for QAW039 in Asthma

Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients

PERFormance Enhancement of the Canadian Nutrition Guidelines by a Tailored Implementation Strategy: The PERFECTIS Study

A Multi-center Study to Assess the Effects of BYM338 on Skeletal Muscle in Sarcopenic Adults

Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis

Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes

A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors

Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

Pharmacokinetics of rFVIIIFc at Two Vial Strengths

Efficacy and Safety of BGG492 in the Treatment of Migraine